Jan 17, 2021 (Heraldkeepers) -- The Global Retinal Vascular Occlusion Market is expected to reach USD 20.7 billion by 2023, and the market is projected to grow at a CAGR of ~ 9.5 % during the forecast period 2017-2023.
Retinal Vascular Occlusion (RVO) is the build-up of fluids in the retina of the eye due to blood clot obstruction, which prevents it from properly filtering light. RVO may result in a sudden loss of vision and is a common vascular disorder and one of the most common causes of vision loss across the globe. RVO is the second most common cause of blindness after diabetic retinopathy. Unilateral RVO affects approximately 80%-85% cases with bilateral RVO affecting the rest. RVO has an incidence rate of 2.2 cases per 1000 of general population older than 40 years and 5.4 cases per 1000 of general population older than 64 years.
High level of blood lipids, or fats, hyperlipidemia, or high blood cholesterol levels, diabetes, cancer, hypothyroidism, biliary cirrhosis, cholestasis, nephrotic syndrome, hematologic diseases such as monoclonal gammopathy and other metabolic disorders are some of the major risk factors.
Get a Sample Copy of This Report @ https://www.marketresearchfuture.com/sample_request/4899 .
Rising demand due to growing geriatric population, increasing screening, greater emphasis on restorative procedures, rising safety, and success of retinal vein occlusion treatment, and others are the major driver of the market. The market may experience lag in the growth due to the complications such as the risk of bleeding, infections, pain, especially during surgery, the high cost of retinal vein occlusion treatment, poor healthcare penetration, especially, the ophthalmic segment, and others.
There is no preventive treatment for retinal vein occlusion, which is the single most unmet need in the market. Product development represents the best strategy for the market growth. The market is expected to witness exponential growth over the review period owing to technological advancement in surgical procedures. Market development is another strategy for as there is a large unmet need in the developing regions such as India and China. Cost of the product is likely to be a decisive factor in the developing regions such as Asia Pacific and, especially, Africa.
Global Retinal Vein Occlusion Market Players
Some of the key players profiled in the report are Regeneron Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals LLC, Novartis AG, Pfizer, Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson, Teva pharmaceutical industries, Novo Nordisk, Sanofi, and others.
The global retinal vascular occlusion market has been segmented on the basis of types, condition, diagnosis, drugs, surgery, and end user.
Based on the types, the market has been segmented as retinal artery occlusion & retinal vascular occlusion.
Based on the condition, the market has been segmented as non-ischemic and ischemic.
Based on the diagnosis, the market has been segmented as fundoscopic examination, optical coherence tomography (OCT), fluorescein angiography, and others.
Based on the drugs, the market has been segmented as an anti-vascular endothelial growth factor (VEGF), corticosteroid, anticoagulants, fibrinolytic, and others.
Based on the surgery, the market has been segmented as laser retinal photocoagulation, chorioretinal venous anastomosis, radial optic neurotomy, and others.
Based on the end user, the market has been segmented as hospitals and clinics, research and academics, and others.
1 Report Prologue
2.1 Scope of Study